ACTR-707 |
|
Phase 1 Clinical |
Unum Therapeutics |
Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
Allogeneic anti-CD20 CAR-T cell therapy (Precision BioSciences) |
PBCAR-20A |
Phase 2 Clinical |
Precision Biosciences |
Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
MB-CART20.1 (Miltenyi Biotec) |
|
Phase 2 Clinical |
Miltenyi Biotec |
Lymphoma, Non-Hodgkin; Melanoma |
Details
|
Ublituximab |
R-603; EMAB-6; TG-1101; TG-1303; LFB-R603; TGTX-1101 |
Phase 3 Clinical |
Tg Therapeutics |
Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Multiple Sclerosis, Relapsing-Remitting; Lymphoma, Large B-Cell, Diffuse; Multiple Sclerosis; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Neuromyelitis Optica; Lymphoma; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
MT-3724 |
MT-3724 |
Phase 2 Clinical |
Molecular Partners Ag |
Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Humanized monoclonal antibody targeting CD20 (Shanghai Pharma) |
B-001 |
Phase 1 Clinical |
Shanghai Pharmaceuticals Holding Co Ltd |
Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Rituximab biosimilar (Boehringer Ingelheim) |
BI-695500 |
Phase 3 Clinical |
C.H. Boehringer Sohn Ag & Co. Kg |
Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin |
Details
|
Plamotamab |
XmAb-13676 |
Phase 1 Clinical |
Xencor |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
MB-106 |
MB-106 |
Phase 2 Clinical |
Fred Hutchinson Cancer Research Center |
Lymphoma, Non-Hodgkin |
Details
|
Rituximab/Paclitaxel |
AR-160 |
Phase 1 Clinical |
Mayo Clinic |
Lymphoma, Non-Hodgkin |
Details
|
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) |
|
Phase 2 Clinical |
Southwest Hospital Chongqing |
Lymphoma, Large B-Cell, Diffuse |
Details
|
CD20 CAR-T cell therapy (Shanghai Longyao Biotechnology) |
|
Phase 1 Clinical |
Shanghai Longyao Biotechnology |
Lymphoma, Non-Hodgkin |
Details
|
Bendamustine Hydrochloride/Rituximab |
|
Phase 1 Clinical |
1globe Biomedical Co Ltd |
Lymphoma, B-Cell |
Details
|
Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein (Fred Hutchinson Cancer Research Center) |
|
Phase 1 Clinical |
Fred Hutchinson Cancer Research Center, National Cancer Institute |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
Anti-CD20 CAR-T cell therapy (Wuhan Bio-Raid) |
|
Clinical |
Wuhan Bio-Raid Biotechnology |
Neoplasms |
Details
|
DI-Leu16-IL2 |
DI-Leu16-IL2 |
Phase 2 Clinical |
Merck Serono |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
MB-CART2019.1 |
MB-CART2019.1 |
Phase 2 Clinical |
Miltenyi Biotec |
Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Recombinant Fc-glycosylated anti-CD20 monoclonal antibody (Bio-Thera Solutions) |
BAT-4306F |
Phase 1 Clinical |
Bio-Thera Solutions Ltd |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
Anti-CD20 CART-transduced T cells (Cellular Biomedicine Group) |
CART-20; CBM-C20.1; CBM-CD20 1 |
Phase 2 Clinical |
Pla General Hospital |
Leukemia; Lymphoma, B-Cell |
Details
|
Rituximab biosimilar (Genor Biopharma) |
GB-241 |
Phase 3 Clinical |
Genor Biopharma Co Ltd, Nanjing Yoko Biomedical Co Ltd |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin |
Details
|
Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University) |
|
Phase 1 Clinical |
First Affiliated Hospital Of Zhejiang University |
Lymphoma, Large B-Cell, Diffuse |
Details
|
Chimeric antigen receptor T-cell therapy (Fred Hutchinson Cancer Research Center) |
|
Phase 2 Clinical |
Fred Hutchinson Cancer Research Center |
Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Rituximab biosimilar (Fred Hutchinson Cancer Research Center) |
|
Phase 1 Clinical |
Fred Hutchinson Cancer Research Center |
Multicentric Castleman's Disease (MCD); Sarcoma, Kaposi |
Details
|
Rituximab biosimilar (International Biotech Center Generium) |
GNR-006 |
Phase 1 Clinical |
International Biotech Center Generium |
Lymphoma, B-Cell |
Details
|
Anti-CD20 allogeneic CAR-T cell therapy (Nanjing Medical University) |
LUCAR-20S |
Phase 1 Clinical |
Nanjing Medical University |
Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
CD19/CD20 Dual-CAR-T cell therapy (HeBei Yanda hospital) |
|
Phase 1 Clinical |
Hebei Yanda Hospital |
Lymphoma, B-Cell |
Details
|
IGN-002 |
IGN-002 |
Phase 1 Clinical |
Immunogen |
Lymphoma, Non-Hodgkin |
Details
|
CD20-CD19 cCAR T cell therapy (iCell Gene Therapeutics) |
|
Phase 1 Clinical |
Icell Gene Therapeutics |
Lymphoma, B-Cell; Leukemia; Leukemia, B-Cell |
Details
|
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) |
4SCAR-T |
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Neoplasms |
Details
|
H02 |
H-02 |
Phase 3 Clinical |
Shandong New Time Pharmaceutical Co Ltd |
Lymphoma, Large B-Cell, Diffuse |
Details
|
Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) |
|
Phase 1 Clinical |
Fujian Medical University |
Lymphoma, Large B-Cell, Diffuse |
Details
|
BCD-132 |
BCD-132 |
Phase 2 Clinical |
Biocad |
Multiple Sclerosis |
Details
|
CD20-directed CAR-T cell therapy (Tongji Hospital) |
C-CAR066 |
|
Tongji Hospital |
|
Details
|
Veltuzumab |
hA20; IMMU-106 |
Phase 2 Clinical |
Immunomedics Inc |
Lymphoma, B-Cell; Purpura, Thrombocytopenic, Idiopathic; Leukemia, Lymphoid; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Pain, Postoperative; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma, Large-Cell, Anaplastic; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic |
Details
|
Dual specificity CD19 and CD20 or CD22 CAR-T cell (Chinese PLA General Hospital) |
|
Phase 2 Clinical |
Pla General Hospital |
Leukemia; Lymphoma, B-Cell |
Details
|
Ocrelizumab biosimilar (CinnaGen) |
|
Phase 3 Clinical |
Cinnagen |
Multiple Sclerosis |
Details
|
Rituximab conjugate (BioIntegrator) |
CON-4619 |
Phase 1 Clinical |
Biointegrator |
Lymphoma, Follicular; Lymphoma, Non-Hodgkin |
Details
|
Anti-CD3 anti-CD20 bispecific antibody (Genmab) |
GEN-3013 |
Phase 2 Clinical |
Genmab |
Hematologic Neoplasms |
Details
|
CD20 x CD3 bispecific antibody (IGM Biosciences) |
IGM-2323 |
Phase 1 Clinical |
Igm Biosciences |
Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin |
Details
|
Recombinant anti-CD20 chimeric monoclonal antibody (Livzon Group) |
LZM-002 |
Phase 1 Clinical |
Livzon Pharmaceutical Group Inc |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin |
Details
|
Rituximab biosimilar (Samsung) |
SAIT-101 |
Phase 3 Clinical |
Samsung Biologics |
Arthritis, Rheumatoid; Lymphoma, Follicular |
Details
|
CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) |
|
Phase 1 Clinical |
Uclas Jonsson Comprehensive Cancer Center |
Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Anti-CLEVER-1 antibodies (Faron Pharmaceuticals) |
FP-1115; FP-1302; FP-1304; FP-1305 |
Phase 2 Clinical |
Faron |
Neoplasms |
Details
|
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) |
|
Phase 1 Clinical |
Henan Provincial Cancer Hospital |
Lymphoma, B-Cell |
Details
|
CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) |
|
Phase 1 Clinical |
Zhejiang University |
Hematologic Neoplasms |
Details
|
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) |
|
Phase 2 Clinical |
The Medical College Of Wisconsin Nonprofit |
Neoplasms |
Details
|
Anti-CD20 CAR T-cell therapy (Shanghai Longyao Biotechnology) |
|
Phase 2 Clinical |
Shanghai Longyao Biotechnology |
Lymphoma, Large B-Cell, Diffuse |
Details
|
BAT-4406F |
BAT-4406; BAT-4406F |
Phase 1 Clinical |
Bio-Thera Solutions Ltd |
Neuromyelitis Optica |
Details
|
Odronextamab |
REGN-1979 |
Phase 2 Clinical |
Regeneron Pharmaceuticals Inc |
Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Rituximab biosimilar (Zhejiang Teruisi Pharmaceutical) |
TRS001 |
Phase 1 Clinical |
Zhejiang Teruisi Pharmaceutical Inc |
Lymphoma |
Details
|
Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Pharma) |
|
Phase 1 Clinical |
Shanghai Pharmaceuticals Holding Co Ltd |
Lymphoma |
Details
|
BVX20-CD20 antibody (Biocon/Vaccinex) |
BVX-20; BVX20-MAb |
Phase 2 Clinical |
Biocon, Vaccinex |
Lymphoma, Non-Hodgkin |
Details
|
CD19/CD20 CAR-T Cell Therapy (PersonGen) |
|
|
|
|
Details
|
LY007 |
LY007 |
Phase 1 Clinical |
Shanghai Longyao Biotechnology |
Lymphoma, Non-Hodgkin |
Details
|
CD19/CD20 dual-target CAR-T cell therapy (Shenzhen University General Hospital) |
|
Phase 2 Clinical |
Shenzhen University General Hospital |
Lymphoma, B-Cell |
Details
|
Recombinant humanized monoclonal antibody MIL62 |
|
Phase 2 Clinical |
Innocare Pharma, Beijing Mabworks Biotech Co Ltd |
Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Non-Hodgkin |
Details
|
MRG001 |
MRG-001 |
Phase 2 Clinical |
Shanghai Miracogen Inc |
Coronavirus Disease 2019 (COVID-19); Lymphoma, Non-Hodgkin |
Details
|
Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Crosslink Pharmaceutical) |
|
Phase 1 Clinical |
Shanghai Crosslink Pharmaceutical R & D Co Ltd |
Lymphoma, Non-Hodgkin |
Details
|
Mosunetuzumab |
RG-7828; BTCT-4465A; RO-7030816 |
Phase 3 Clinical |
Genentech Inc |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Rituximab biosimilar (Gedeon Richter) |
RGB-03 |
Phase 1 Clinical |
Gedeon Richter |
Arthritis, Rheumatoid |
Details
|
Glofitamab |
RG-6026; RO-7082859 |
Phase 3 Clinical |
F. Hoffmann-La Roche Ltd |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma |
Details
|
Anti-CD20 CAR-T (Legend) |
|
Phase 1 Clinical |
|
Lymphoma |
Details
|
Rituximab biosimilar (Hisun Pharma/Beijing Mabworks Biotech) |
|
Phase 3 Clinical |
Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin |
Details
|
IMM-0306 |
IMM-0306 |
Phase 1 Clinical |
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd |
Lymphoma, B-Cell |
Details
|
Rituximab biosimilar (CTTQ Pharma) |
TQB-2303 |
Phase 3 Clinical |
Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin |
Details
|
Rituximab biosimilar (Shenzhen Main Luck Pharmaceuticals) |
|
Phase 1 Clinical |
Shenzhen Main Luck Pharmaceuticals Inc |
Arthritis, Rheumatoid; Lymphoma |
Details
|
TRS-005 |
TRS-005 |
Phase 1 Clinical |
Zhejiang Teruisi Pharmaceutical Inc |
Lymphoma, Non-Hodgkin |
Details
|
Recombinant chimeric anti-CD20 antibody (Shanghai Institute of Biological Products) |
|
Phase 3 Clinical |
Shanghai Institute Of Biological Products Co Ltd |
Lymphoma, Large B-Cell, Diffuse |
Details
|
Rituximab biosimilar (Hualan Biological Engineering) |
WBP-263 |
Phase 3 Clinical |
Hualan Genetic Engineering Co Ltd |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin |
Details
|